Subjects: FARMACOGENÉTICA, HIPERPLASIA SUPRARRENAL CONGÊNITA, HIDROXILASE (DEFICIÊNCIA)
ABNT
MOREIRA, Ricardo P. P. et al. Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinics, v. 66, n. 8, p. 1361-1365, 2011Tradução . . Disponível em: https://doi.org/10.1590/S1807-59322011000800009. Acesso em: 02 out. 2024.APA
Moreira, R. P. P., Jorge, A. A. L., Gomes, L. G., Kaupert, L. C., Massud Filho, J., Mendonca, B. B., & Bachega, T. A. S. S. (2011). Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinics, 66( 8), 1361-1365. doi:10.1590/S1807-59322011000800009NLM
Moreira RPP, Jorge AAL, Gomes LG, Kaupert LC, Massud Filho J, Mendonca BB, Bachega TASS. Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency [Internet]. Clinics. 2011 ; 66( 8): 1361-1365.[citado 2024 out. 02 ] Available from: https://doi.org/10.1590/S1807-59322011000800009Vancouver
Moreira RPP, Jorge AAL, Gomes LG, Kaupert LC, Massud Filho J, Mendonca BB, Bachega TASS. Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency [Internet]. Clinics. 2011 ; 66( 8): 1361-1365.[citado 2024 out. 02 ] Available from: https://doi.org/10.1590/S1807-59322011000800009